Source comparison
GHRP-2 Acetate vs Hexarelin: Peptide Comparison
The table below summarizes the key pharmacological, dosing, and application differences between GHRP-2 Acetate and Hexarelin based on peer-reviewed research and observed kinetics in controlled studies. GH Peak Potency (100mcg dose) Moderate. Produces 8–12 ng/m
This comparison does not assign a generated winner or score.
- The table below summarizes the key pharmacological, dosing, and application differences between GHRP-2 Acetate and Hexarelin based on peer-reviewed research and observed kinetics in controlled studies.
- GH Peak Potency (100mcg dose)
- Moderate. Produces 8–12 ng/mL peak GH in most models
- High. Produces 15–22 ng/mL peak GH in first-week administration
- Hexarelin delivers stronger acute GH pulses initially
- Receptor Desensitization Timeline
- Slow. GH response declines ~18–22% by week 4 of daily dosing
- Rapid. GH response declines ~40–50% by week 2 of daily dosing
- GHRP-2 Acetate maintains consistency longer
- Cortisol Elevation (per dose)
- Mild. Approximately 4 mcg/dL above baseline
- High. Approximately 12 mcg/dL above baseline
- Hexarelin produces 3x higher cortisol spikes
- Prolactin Elevation (per dose)
- Low. Approximately 6 ng/mL above baseline
- Moderate. Approximately 18 ng/mL above baseline
- GHRP-2 Acetate has lower prolactin impact
- Typical Dosing Range
- 100–300mcg per dose, 2–3x daily
- 100–200mcg per dose, 1–2x daily with cycling
- Hexarelin requires cycling; GHRP-2 can run continuously
- Optimal Study Duration
- 4–6 weeks continuous before washout needed
- 2 weeks on, 1 week off cycling to preserve response
- Protocol design depends on study length
- Best Use Case
- Sustained multi-week GH studies with minimal cortisol confounds
- Short-duration studies requiring maximal acute GH secretion
- Choose based on endpoint timeline and hormonal tolerance